Abstract
Objective
To evaluate the efficacy and tolerability of sorafenib combined with cryoablation in treating unresectable hepatocellular carcinoma (HCC).
Methods
Patients with unresectable advanced HCC received cryoablation and sorafenib at a dose of 400 mg twice daily in 4-week cycles on the same day of the cryoablation. Tumor response, median overall survival and the median time to radiological progression were calculated and the toxicity was evaluated.
Results
Seventy-eight patients with unresectable HCC were involved in this study. The median age was 52 years (range, 22–81 years). The Eastern Cooperative Oncology Group (ECOG) performance status scores were 0 (39.7%), 1 (55.1%), and 2 (5.1%). Nine (11.5%) patients were at Barcelona clinic liver cancer (BCLC) stage A, twenty-four (30.8%) patients were at stage B and 45 (57.7%) patients were at stage C. Five (6.4%) achieved partial responses, and 34 (43.6%) achieved stable disease. The median time to progression (TTP) for all enrolled patients was 6.6 months and the median overall survival (OS) was 12.2 months.
Conclusion
Cryoablation combined with sorafenib demonstrates good efficacy and acceptable tolerability in treating unresectable advanced HCC patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74–108.
Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698–711
Finlay IG, Seifert JK, Stewart GJ, et al. Resection with cryotherapy of colorectal hepatic metastases has the same survival as hepatic resection alone. Eur J Surg Oncol 2000; 26:199–202.
Kohli V, Clavien PA. Cryoablation of liver tumours. Br J Surg 1998; 85:1171–1172.
Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1999; 23:109–113.
Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2008; 2:779–788.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378–390.
Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421–430.
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19:329–338.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216.
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751–755.
Adam R, Akpinar E, Johann M, et al. Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg 1997; 225:39–48.
Xu KC, Niu LZ, He WB, et al. Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol 2003; 9:2686–2689.
Weber SM, Lee FT Jr, Chinn DO, et al. Perivascular and intralesional tissue necrosis after hepatic cryoablation: results in a porcine model. Surgery 1997; 122:742–747.
Puglisi F, Scalone S, DiLauro V. Angiogenesis and tumor growth. N Engl J Med 1996; 334:921.
Cheng A, Kang Y, Chen C, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008; 26(Suppl):4509.
Plastaras JP, Kim SH, Liu YY, et al. Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007; 67:9443–9454.
Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115:428–436.
Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22:4442–4445.
Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol 2008; 26:5845–5848.
Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154–2160.
Clavien PA, Kang KJ, Selzner N, et al. Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis. J Gastrointest Surg 2002; 6:95–101.
Akaza H, Tsukamoto T, Murai M, et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37:755–762.
Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99:159–165.
Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45:721–724.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ni, H., Yang, M., Guo, Z. et al. Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. Chin. J. Cancer Res. 23, 188–193 (2011). https://doi.org/10.1007/s11670-011-0188-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11670-011-0188-y